BGB-A425
12 Apr 2022
Trial Summary
BGB-A425 is a humanized, immunoglobulin gamma-1 (IgG1)-variant monoclonal antibody against TIM-3. Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD-1. This study tests the safety and anti-tumor effect of BGB-A425 in combination with tislelizumab in participants with advanced solid tumors.
Acronym:
BGB-A425
ACTRN/NCT /ethics:
NCT03744468
Scientific title:
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Sponsor / Cooperative group:
BeiGene
Trial & Patient Characteristics
| Cancer Type | All cancers; Lung & mesothelioma; Head & neck |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase II |
| Age Range | 18+ years |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2018-11-13 |
| Anticipated End Date | 2024-01-01 |
Participating Hospitals
| Hospital | Calvary North Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Vy Broadbridge |
| Recruitment Status | Recruiting |